728917-18-8

Veltuzumab (i.v. or s.c.; 5, 20 and 60 μg; single) can control tumor growth or deplete circulating or sessile B cells at low doses in mouse models of intraperitoneal and subcutaneous doses^[1].
Veltuzumab (i.p.; 0.05-35 μg) are significantly effective in vivo^[1].